The termination removes a key catalyst for BioNTech's mRNA monotherapy thesis in CRC, an immunologically cold tumor. Monitor for full data analysis and any read-through to the ongoing PDAC combination trial. The stock may see pressure from this de-risking failure, but the broader oncology pipeline and COVID franchise provide a buffer.
Price Chart
Executive Summary
BioNTech announced termination of the Phase 2 trial (BNT122-01) of autogene cevumeran as monotherapy in resected colorectal cancer after a DSMB recommendation citing a numerical overall survival imbalance and futility. The decision follows a prior futility boundary crossing in October 2025. The separate Phase 2 PDAC trial (IMcode003) combining autogene cevumeran with checkpoint inhibition continues unaffected. This is a meaningful pipeline setback for BioNTech's mRNA cancer immunotherapy platform in a key indication, though the company has multiple other oncology programs.
Key Facts
- BioNTech terminated Phase 2 trial BNT122-01 of autogene cevumeran in ctDNA-positive resected Stage II/III colorectal cancer.
- DSMB recommended termination after identifying a numerical imbalance in overall survival between treatment arms; no new safety signals.
- Futility boundary was crossed in October 2025 but DSMB deemed data immature at that time.
- The separate Phase 2 PDAC trial (IMcode003, NCT05968326) evaluating autogene cevumeran in combination with checkpoint inhibition and chemotherapy continues as planned.
- Autogene cevumeran is jointly developed with Genentech (Roche).
Financial Impact
Pipeline setback in colorectal cancer; no financial figures disclosed in filing. BioNTech has a $28B market cap with multiple other oncology programs.
Risk Factors
- Negative overall survival signal may raise questions about mRNA monotherapy efficacy in cold tumors.
- Potential for further pipeline delays or reprioritization if other monotherapy trials face similar challenges.
- Partner Genentech may reassess commitment to the mRNA cancer immunotherapy collaboration.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000061 |
| Document: 0001776985-26-000061-index-headers.html | 0001776985-26-000061 |
| Document: 0001776985-26-000061-index.html | 0001776985-26-000061 |
| Document: 0001776985-26-000061.txt | 0001776985-26-000061 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.97 (−1.91%) |
Sep 14, 2026 18d ago | Press Release | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.97 (−1.91%) |
Aug 28, 2026 5w ago | 6-K | $102.08 $103.76 | ▼ −1.65% | ▼ −1.54% | $96.97 (+5.00%) |
Aug 20, 2026 6w ago | 6-K | $110.89 $111.40 | ▲ +0.46% | ▼ −0.65% | $96.97 (−12.55%) |
Aug 11, 2026 7w ago | Institutional Cluster | $92.80 $92.75 | ▼ −0.05% | ▲ +0.35% | $96.97 (+4.50%) |
Aug 4, 2026 8w ago | 6-K | $91.35 $92.80 | ▼ −1.59% | ▼ −1.69% | $96.97 (−6.16%) |
Aug 3, 2026 8w ago | 6-K | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.97 (+5.12%) |
Aug 3, 2026 8w ago | Press Release | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.97 (+5.12%) |
Jul 29, 2026 9w ago | 6-K | $92.85 $91.19 | ▼ −1.79% | ▼ −5.41% | $96.97 (+4.44%) |
Jun 8, 2026 16w ago | 6-K | $85.50 $90.80 | ▲ +6.20% | ▲ +4.09% | $96.97 (+13.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access